HGEN - Why Humanigen Stock Is Skyrocketing Today
Shares of clinical-stage biopharmaceutical company Humanigen (NASDAQ: HGEN) are soaring through the roof on Monday after the company reported positive top-line results from a clinical trial for one of its pipeline candidates, lenzilumab. As of 1:20 p.m. EDT, the company's stock was up by 66.6% after jumping by as much as 108.7% earlier today.
Lenzilumab is an experimental treatment for COVID-19. In a phase 3 clinical trial on patients hospitalized with the disease, those who received lenzilumab and other treatments (including steroids and remdesivir, an antiviral medicine for COVID-19 marketed by Gilead Sciences ), were 54% more likely to survive without the assistance of mechanical ventilation than those who received a placebo and other treatments.
Image source: Getty Images.
For further details see:
Why Humanigen Stock Is Skyrocketing Today